Financial Performance - The company's revenue for the year ended December 31, 2021, was approximately RMB 925.3 million, an increase of 44.1% compared to RMB 642.3 million in 2020[8]. - Gross profit for the same period was approximately RMB 747.5 million, reflecting a 45.7% increase from RMB 513.1 million in the previous year[12]. - Net profit attributable to the company's owners was approximately RMB 292.5 million, up 35.4% from RMB 216.1 million in 2020[12]. - The company achieved a basic earnings per share of RMB 6.8 cents, a 36.0% increase from RMB 5.0 cents in the prior year[8]. - The operating profit increased by approximately 24.3% to about RMB 328.7 million from RMB 264.5 million in the previous year[32]. - Revenue from the structural heart disease business was approximately RMB 331.1 million, representing a growth of about 60.4% from RMB 206.4 million in the previous year[23]. - Revenue from the peripheral vascular business was approximately RMB 548.5 million, an increase of about 33.4% from RMB 411.3 million in the previous year[24]. - The total comprehensive income for the year was RMB 285,423 thousand, compared to RMB 208,080 thousand in 2020, reflecting a growth of 37%[195]. Regulatory Approvals and Product Development - The company has received regulatory approval for several key products, including the G-iliac™ iliac artery bifurcation stent system and the LAxible™ left atrial appendage occluder[13]. - The IBS™ absorbable drug-eluting coronary stent system has received implied permission for confirmatory clinical trials in China, with a 100% success rate in initial human clinical trials[13]. - The company has 14 products recognized as innovative medical devices by the National Medical Products Administration[13]. - The company is focusing on developing a fourth-generation congenital heart disease occluder to meet diverse patient needs, indicating ongoing product innovation[52]. Market Performance and Sales - The sales in mainland China accounted for approximately 83.6% of total revenue for the year ended December 31, 2021, compared to 83.9% in 2020[18]. - The company's domestic sales grew by approximately 43.6% year-on-year, primarily due to the containment of the COVID-19 pandemic and increased market penetration of its products[18]. - The overseas sales increased by approximately 46.4% compared to the same period in 2020, driven by effective marketing strategies[18]. - Revenue from the European market accounted for approximately 7.4% of total revenue, down from 9.0% in 2020, indicating a slight decline in contribution from this region[48]. Financial Position and Assets - The total assets of the company as of December 31, 2021, were RMB 3,183.7 million, compared to RMB 2,954.5 million in 2020[9]. - The company's total current assets as of December 31, 2021, were approximately RMB 1,837.1 million, up from RMB 1,544.8 million in 2020[37]. - Cash and cash equivalents increased by approximately 15.2% to RMB 1,119.3 million as of December 31, 2021, from RMB 971.7 million in 2020[39]. - The company had no bank borrowings as of December 31, 2021, down from RMB 174.5 million in 2020, resulting in a debt-to-equity ratio of zero[40]. - The total equity attributable to owners was approximately RMB 2,503.6 million as of December 31, 2021, compared to RMB 2,340.1 million in 2020[41]. Research and Development - Research and development expenses decreased by 12.8% to approximately RMB 145.9 million, with capitalized development expenditures of approximately RMB 66.6 million[31]. - The company reported a capitalized development cost of RMB 288,762,000 as of December 31, 2021, related to products for structural heart disease and peripheral vascular disease[187]. Corporate Governance - The company has adopted corporate governance principles in compliance with the Hong Kong Stock Exchange's listing rules, ensuring adherence to the corporate governance code throughout the fiscal year ending December 31, 2021[71]. - The board consists of two executive directors, one non-executive director, and three independent non-executive directors as of the report date[73]. - The company has established internal guidelines requiring board approval for significant investments and changes in business strategy[74]. - The independent non-executive directors have confirmed their independence in accordance with listing rules[74]. Employee and Workforce Management - The company employs 943 full-time employees as of December 31, 2021, an increase from 791 in 2020, reflecting growth in workforce[55]. - Total employee costs, including director remuneration, were approximately RMB 225.8 million for the year ended December 31, 2021, down from RMB 314.6 million in 2020[55]. - The company emphasizes the importance of employee welfare, providing a safe working environment and equal employment opportunities[57]. Environmental and Social Responsibility - The company is committed to creating environmentally friendly and sustainable business operations, investing in energy-saving technologies to reduce carbon emissions[60]. - The company plans to release a separate report detailing its environmental and social performance data[60]. Shareholder Relations and Transparency - The annual general meeting serves as a primary channel for communication with shareholders, allowing direct interaction with the board[102]. - The company emphasizes maintaining high transparency to enhance investor relations and regularly communicates with institutional investors and analysts[101]. - The company’s website serves as a communication platform for public and shareholder updates on business developments and financial performance[101].
先健科技(01302) - 2021 - 年度财报